Dr. Dennis L. Cooper, MD

Dr. Cooper practices at Montefiore Einstein Hospital-Moses Campus in Bronx, New York, part of Montefiore Einstein.

Dr. Cooper's NPI, 1154319093, was assigned on October 13, 2005. Dr. Cooper graduated from Rush Medical College in 1979. Dr. Cooper holds Connecticut license 022637.

Dr. Cooper's primary practice is Montefiore Einstein Hospital-Moses Campus, at 111 East 210th Street, Bronx, NY 10467 in Bronx County. The practice phone is (718) 920-4321.

Dr. Cooper's primary practice is Montefiore Einstein Hospital-Moses Campus in Bronx, New York, part of Montefiore Einstein. The medical group on file is Montefiore Einstein Faculty Practice Group. Dmand AI also links Dr. Cooper to 1 more school health center, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cooper practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Cooper's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Cooper is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Cooper's licenses on file in 4 states: Connecticut, New York, New Jersey and Pennsylvania.

Dmand AI lists lymphoma and multiple myeloma among the conditions Dr. Cooper treats.

CMS data shows 122 Medicare services from Dr. Cooper across 2 procedure codes in 2024, for 53 Medicare patients. Medicare paid $12,210 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 53 Medicare patients who saw Dr. Cooper in 2024. The largest group is 65 to 74, with 23 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 38% are also on Medicaid. Their average risk score is 3.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cooper's median patient age at 68, with 45% women.

In 2024, Dr. Cooper wrote 190 Medicare Part D claims for 24 patients. 93% of them were for generic drugs. CMS names the drug for 60 of them, across 3 drugs with 11 or more claims each, at $1,108 in total drug cost. In 2023, CMS named 24 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Cooper for performance year 2024, reported as part of a group. CMS lists Dr. Cooper as offering telehealth.

Dmand AI links 146 papers to Dr. Cooper, published from 2003 to 2025. 2024 was the busiest year, with 10. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation and Multiple Myeloma. Dr. Cooper has published most often in Bone Marrow Transplant. Dr. Cooper's most frequent co-authors are Mendel Goldfinger, MD, Nishi Shah, MD and Noah Saul Kornblum, MD.

Dmand AI links Dr. Cooper to 5 clinical trials, 2 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Open Payments lists research payments to Dr. Cooper that name 1 trial.

CMS Open Payments shows 191 general payments to Dr. Cooper from 17 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 40% of the total. Seagen Inc. paid the most, $132,465. It also lists 17 research payments totaling $5,280 from 2019 to 2022, naming 1 clinical trial.

Dr. Cooper graduated from Rush Medical College in 1979.

Dr. Cooper is in network with 11 carriers, including Aetna, United Healthcare and Horizon Blue Cross Blue Shield of New Jersey. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.